GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RAPT Therapeutics Inc (NAS:RAPT) » Definitions » Price-to-Owner-Earnings

RAPT Therapeutics (RAPT Therapeutics) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is RAPT Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-24), RAPT Therapeutics's share price is $4.20. RAPT Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for RAPT Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


RAPT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.4
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), RAPT Therapeutics's share price is $4.20. RAPT Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.08. Therefore, RAPT Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-24), RAPT Therapeutics's share price is $4.20. RAPT Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.08. Therefore, RAPT Therapeutics's PE Ratio without NRI for today is At Loss.


RAPT Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for RAPT Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAPT Therapeutics Price-to-Owner-Earnings Chart

RAPT Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

RAPT Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of RAPT Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, RAPT Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RAPT Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RAPT Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where RAPT Therapeutics's Price-to-Owner-Earnings falls into.



RAPT Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

RAPT Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.20/-3.14
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RAPT Therapeutics  (NAS:RAPT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


RAPT Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of RAPT Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


RAPT Therapeutics (RAPT Therapeutics) Business Description

Traded in Other Exchanges
Address
561 Eccles Avenue, South San Francisco, CA, USA, 94080
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Executives
Dirk G. Brockstedt officer: Chief Scientific Officer C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
William Ho officer: Chief Medical Officer 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendye Robbins director C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA 94080
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Rodney Kb Young officer: Chief Financial Officer STEMCELLS, INC., 3155 PORTER DRIVE, PALO ALTO CA 94304
Lori Lyons-williams director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Column Group Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Ii Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp 10 percent owner 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158